Literature DB >> 30995092

Role of Virtual Biopsy in the Management of Renal Masses.

Alberto Diaz de Leon1, Matthew S Davenport2, Stuart G Silverman3, Nicola Schieda4, Jeffrey A Cadeddu1,5, Ivan Pedrosa1,5,6.   

Abstract

OBJECTIVE. Renal masses comprise a heterogeneous group of pathological conditions, including benign and indolent diseases and aggressive malignancies, complicating management. In this article, we explore the emerging role of imaging to provide a comprehensive noninvasive characterization of a renal mass-so-called "virtual biopsy"-and its potential use in the management of patients with renal tumors. CONCLUSION. Percutaneous renal mass biopsy (RMB) remains a valuable method to provide a presurgical histopathologic diagnosis of renal masses, but it is an invasive procedure and is not always feasible. Accumulating data support the use of imaging features to predict histopathology of renal masses. Imaging may help address some of the inherent limitations of RMB, and in certain settings, a multimodal clinical approach may allow decreasing the need for RMB.

Entities:  

Keywords:  CT; MRI; renal cell carcinoma; renal mass; renal mass biopsy

Year:  2019        PMID: 30995092      PMCID: PMC6800762          DOI: 10.2214/AJR.19.21172

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  67 in total

1.  MR classification of renal masses with pathologic correlation.

Authors:  Ivan Pedrosa; Mary T Chou; Long Ngo; Ronaldo H Baroni; Elizabeth M Genega; Laura Galaburda; William C DeWolf; Neil M Rofsky
Journal:  Eur Radiol       Date:  2007-09-26       Impact factor: 5.315

2.  Subtype differentiation of renal cell carcinoma using diffusion-weighted and blood oxygenation level-dependent MRI.

Authors:  Youn Ah Choi; Chan Kyo Kim; Sung Yoon Park; Seong Whi Cho; Byung Kwan Park
Journal:  AJR Am J Roentgenol       Date:  2014-07       Impact factor: 3.959

3.  Prediction of growth rate of solid renal masses: utility of MR imaging features--preliminary experience.

Authors:  Katerina Dodelzon; Thais C Mussi; James S Babb; Samir S Taneja; Andrew B Rosenkrantz
Journal:  Radiology       Date:  2012-01-20       Impact factor: 11.105

Review 4.  Diagnostic accuracy of segmental enhancement inversion for diagnosis of renal oncocytoma at biphasic contrast enhanced CT: systematic review.

Authors:  Nicola Schieda; Matthew D F McInnes; Lilly Cao
Journal:  Eur Radiol       Date:  2014-03-26       Impact factor: 5.315

5.  Diffusion-weighted MRI in renal cell carcinoma: a surrogate marker for predicting nuclear grade and histological subtype.

Authors:  Ankur Goyal; Raju Sharma; Ashu S Bhalla; Shivanand Gamanagatti; Amlesh Seth; Venkateswaran K Iyer; Prasenjit Das
Journal:  Acta Radiol       Date:  2012-04-01       Impact factor: 1.990

6.  Prospective Evaluation of (99m)Tc-sestamibi SPECT/CT for the Diagnosis of Renal Oncocytomas and Hybrid Oncocytic/Chromophobe Tumors.

Authors:  Michael A Gorin; Steven P Rowe; Alexander S Baras; Lilja B Solnes; Mark W Ball; Phillip M Pierorazio; Christian P Pavlovich; Jonathan I Epstein; Mehrbod S Javadi; Mohamad E Allaf
Journal:  Eur Urol       Date:  2015-09-18       Impact factor: 20.096

7.  Tumor size is associated with malignant potential in renal cell carcinoma cases.

Authors:  R Houston Thompson; Jordan M Kurta; Matthew Kaag; Satish K Tickoo; Shilajit Kundu; Darren Katz; Lucas Nogueira; Victor E Reuter; Paul Russo
Journal:  J Urol       Date:  2009-03-14       Impact factor: 7.450

8.  Differentiation of Clear Cell Renal Cell Carcinoma From Other Subtypes and Fat-Poor Angiomyolipoma by Use of Quantitative Enhancement Measurement During Three-Phase MDCT.

Authors:  See Hyung Kim; Chan Sun Kim; Mi Jeong Kim; Jeong Yeon Cho; Seung Hyun Cho
Journal:  AJR Am J Roentgenol       Date:  2016-01       Impact factor: 3.959

9.  Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes--correlation with pathologic findings.

Authors:  Maryellen R M Sun; Long Ngo; Elizabeth M Genega; Michael B Atkins; Myra E Finn; Neil M Rofsky; Ivan Pedrosa
Journal:  Radiology       Date:  2009-03       Impact factor: 11.105

10.  The Genomic Landscape of Renal Oncocytoma Identifies a Metabolic Barrier to Tumorigenesis.

Authors:  Shilpy Joshi; Denis Tolkunov; Hana Aviv; Abraham A Hakimi; Ming Yao; James J Hsieh; Shridar Ganesan; Chang S Chan; Eileen White
Journal:  Cell Rep       Date:  2015-11-19       Impact factor: 9.423

View more
  6 in total

1.  Apparent Diffusion Coefficient Distinguishes Malignancy in T1-Hyperintense Small Renal Masses.

Authors:  Daniel R Ludwig; David H Ballard; Anup S Shetty; Cary L Siegel; Motoyo Yano
Journal:  AJR Am J Roentgenol       Date:  2019-10-01       Impact factor: 3.959

2.  Transfer learning-based approach for automated kidney segmentation on multiparametric MRI sequences.

Authors:  Rohini Gaikar; Fatemeh Zabihollahy; Mohamed W Elfaal; Azar Azad; Nicola Schieda; Eranga Ukwatta
Journal:  J Med Imaging (Bellingham)       Date:  2022-06-16

Review 3.  How We Do It: Managing the Indeterminate Renal Mass with the MRI Clear Cell Likelihood Score.

Authors:  Ivan Pedrosa; Jeffrey A Cadeddu
Journal:  Radiology       Date:  2021-12-14       Impact factor: 29.146

Review 4.  A 25 year perspective on the evolution and advances in an understanding of the biology, evaluation and treatment of kidney cancer.

Authors:  Daniel M Geynisman; Jodi K Maranchie; Mark W Ball; Gennady Bratslavsky; Eric A Singer
Journal:  Urol Oncol       Date:  2021-06-04       Impact factor: 2.954

5.  Association of Clear Cell Likelihood Score on MRI and Growth Kinetics of Small Solid Renal Masses on Active Surveillance.

Authors:  Robert G Rasmussen; Yin Xi; R Carson Sibley; Christopher J Lee; Jeffrey A Cadeddu; Ivan Pedrosa
Journal:  AJR Am J Roentgenol       Date:  2021-07-21       Impact factor: 6.582

6.  Differentiation of Clear Cell Renal Cell Carcinoma from other Renal Cell Carcinoma Subtypes and Benign Oncocytoma Using Quantitative MDCT Enhancement Parameters.

Authors:  Claudia-Gabriela Moldovanu; Bianca Petresc; Andrei Lebovici; Attila Tamas-Szora; Mihai Suciu; Nicolae Crisan; Paul Medan; Mircea Marian Buruian
Journal:  Medicina (Kaunas)       Date:  2020-10-28       Impact factor: 2.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.